ONC (BeOne Medicines) E10: $-10.28 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ONC BeOne Medicines Ltd ONC
80 GF Score
Price $359.27
GF Value $376.22
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is BeOne Medicines E10?

BeOne Medicines ONC +0.08% 80 E10 is $-10.28 as of Jun. 2026. GuruFocus rates ONC with a GF Score™ of 80/100 and a GF Value™ of $376.22 (Fairly Valued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

BeOne Medicines's adjusted earnings per share data for the three months ended in Jun. 2026 was $2.080. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-10.28 for the trailing ten years ended in Jun. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-08-12), BeOne Medicines's current stock price is $359.27. BeOne Medicines's E10 for the quarter that ended in Jun. 2026 was $-10.28. BeOne Medicines's Shiller PE Ratio of today is .


BeOne Medicines  (NAS:ONC) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


BeOne Medicines E10 Related Terms


BeOne Medicines E10 Historical Data

* Premium members only.

The historical data trend for BeOne Medicines's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BeOne Medicines E10 Chart

BeOne Medicines Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 -10.86 -10.75

BeOne Medicines Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -11.13 -10.95 -10.75 -10.54 -10.28

ONC vs ALNY, RVMD, RPRX: E10 Comparison

For the Biotechnology subindustry, BeOne Medicines's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BeOne Medicines Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BeOne Medicines's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where BeOne Medicines's Shiller PE Ratio falls into.


ONC
80GF Score
BeOne Medicines Ltd ONC
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BeOne Medicines E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, BeOne Medicines's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=2.08/108.5600*108.5600
=2.080

Current CPI (Jun. 2026) = 108.5600.

BeOne Medicines Quarterly Data

per share eps CPI Adj_EPS
201609 -1.040 99.604 -1.134
201612 -0.948 99.380 -1.036
201703 -1.300 100.040 -1.411
201706 -1.560 100.285 -1.689
201709 2.600 100.254 2.815
201712 -2.181 100.213 -2.363
201803 -2.080 100.836 -2.239
201806 -2.860 101.435 -3.061
201809 -2.470 101.246 -2.648
201812 -4.550 100.906 -4.895
201903 -2.860 101.571 -3.057
201906 -1.430 102.044 -1.521
201909 -5.070 101.396 -5.428
201912 -6.370 101.063 -6.843
202003 -4.703 101.048 -5.053
202006 -4.290 100.743 -4.623
202009 -4.811 100.585 -5.192
202012 -5.200 100.241 -5.632
202103 0.650 100.800 0.700
202106 -5.230 101.352 -5.602
202109 -4.723 101.533 -5.050
202112 -6.110 101.776 -6.517
202203 -4.290 103.205 -4.513
202206 -5.460 104.783 -5.657
202209 -5.330 104.835 -5.519
202212 -4.290 104.666 -4.450
202303 -3.380 106.245 -3.454
202306 -3.640 106.576 -3.708
202309 1.950 106.570 1.986
202312 -3.510 106.461 -3.579
202403 -2.470 107.355 -2.498
202406 -1.170 107.991 -1.176
202409 -1.170 107.468 -1.182
202412 -1.430 107.128 -1.449
202503 0.000 107.722 0.000
202506 0.780 108.075 0.783
202509 1.040 107.710 1.048
202512 0.520 107.200 0.527
202603 1.950 108.060 1.959
202606 2.080 108.560 2.080

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of $-10.28 mean?
BeOne Medicines (ONC) has a E10 of $-10.28 as of Jun. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on BeOne Medicines and its competitors.
Is BeOne Medicines' E10 too high?
BeOne Medicines' current E10 is $-10.28. Overall, BeOne Medicines has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BeOne Medicines' E10 compare to ALNY and RVMD?
BeOne Medicines' E10 of $-10.28 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on BeOne Medicines and its competitors. BeOne Medicines's current E10 is $-10.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BeOne Medicines stock overvalued right now?
Based on GuruFocus' analysis, BeOne Medicines (ONC) is currently considered Fairly Valued. The stock's GF Value™ is $376.22, compared to a current price of $359.27 — trading 4.5% below its estimated fair value. The current E10 is $-10.28. BeOne Medicines' overall GF Score™ is 80/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For BeOne Medicines (ONC), the current E10 is $-10.28 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BeOne Medicines (ONC) Overvalued in 2026?

Based on GuruFocus' analysis, BeOne Medicines stock appears to be undervalued. The current stock price of $359.27 is trading 4.5% below its estimated GF Value™ of $376.22. GuruFocus considers BeOne Medicines to be Fairly Valued.

Key valuation signals for ONC:

  • E10: $-10.28
  • GF Value™: $376.22 vs. price of $359.27 (4.5% below fair value)
  • GF Score™: 80/100 with 5 warning signs

No single metric tells the full story. See the ONC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BeOne Medicines Business Description

Address c/o BeOne Medicines I GmbH, 94 Aeschengraben 27, 21st Floor, Basel, CHE, 4051
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
80GF Score

Get the complete analysis for ONC

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$359.27
Price
$376.22
GF Value